Skip to main content

Why register?

In this webinar, Dr. Priyaranjan Pattanaik, Head of NBE services at APSL, provides a comprehensive perspective of the ever-evolving science of Antibody Drug Conjugates (ADC).

This webinar gives a review of pathbreaking trends in the field to help you and your team plan your approach for your ongoing and future ADC discovery and development programs.

#

Date 27 January, 2022

Gain insights on

How new ADC designs revolutionize the payload delivery mechanism, thus unlocking new therapeutic areas

How the ADC approach enhances biological effectiveness of chimeric protein degrader molecules with poor in vivo properties

New avenues in the ADC field, including dual payload strategy, novel linker platforms and antibody enhancements

The Presenter

Priyaranjan Pattanaik

Dr. Priyaranjan Pattanaik

Head, NBE services

Dr. Priyaranjan Pattanaik heads the NBE division at Aurigene Pharmaceutical Services Limited, engaged with discovery and development of large molecule drugs and critical bio-reagents. Priyaranjan is a structural biologist with ~18 years of experience in industry and academia. Priyaranjan has led many large molecule discovery collaborations with innovator pharma companies involving antibodies, ADC, mRNA and bi-specific modalities that have resulted in development and clinical candidates. Priyaranjan is passionate about new technologies and their application in accelerating progression of drug candidates from concept to clinic. As a business leader engaged with global clientele, Priyaranjan believes in a people-centric approach to successful collaborations underpinned by transparent communication, high integrity and a shared vision of bringing new therapies to patients faster and, in a cost effective way.
Priyaranjan received his Ph. D from Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bangalore. He carried out post-doctoral research in Medical School of Case Western Reserve University at Cleveland, Ohio, USA on structure based NCE discovery against bacterial antibiotic resistance.

About Us

Aurigene Pharmaceutical Services Limited is a leading contract research, development and manufacturing organization (CDMO). With a strong legacy of services in discovery, development and manufacturing we are ideally positioned to serve global pharma and specialty companies worldwide.

Our Past Webinar

How an integrated CDMO Accelerates

Drug Discovery Services Opportunities

© 2022 Aurigene Pharmaceutical Services Ltd. All rights reserved.

Please read the legal notice for further details. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Aurigene Pharmaceutical Services Limited, or its subsidiaries or affiliates.